Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4-5 vaccine and practical application of dried blood spots.
Kawasuji H, Morinaga Y, Tani H, Yamada H, Yoshida Y, Ezaki M, Koshiyama Y, Takegoshi Y, Kaneda M, Murai Y, Kimoto K, Nagaoka K, Niimi H, Yamamoto Y. Kawasuji H, et al. Among authors: koshiyama y. Vaccine. 2024 Sep 17;42(22):126029. doi: 10.1016/j.vaccine.2024.05.077. Epub 2024 Jun 4. Vaccine. 2024. PMID: 38839519 Free article.
High Incidence of Metastatic Infections in Panton-Valentine Leucocidin-Negative, Community-Acquired Methicillin-Resistant Staphylococcus aureus Bacteremia: An 11-Year Retrospective Study in Japan.
Kawasuji H, Ikezawa Y, Morita M, Sugie K, Somekawa M, Ezaki M, Koshiyama Y, Takegoshi Y, Murai Y, Kaneda M, Kimoto K, Nagaoka K, Niimi H, Morinaga Y, Yamamoto Y. Kawasuji H, et al. Among authors: koshiyama y. Antibiotics (Basel). 2023 Oct 6;12(10):1516. doi: 10.3390/antibiotics12101516. Antibiotics (Basel). 2023. PMID: 37887217 Free PMC article.
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice.
Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ohama H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tada F, Nakamura S, Nakamura Y, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Tanaka H, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; RELPEC Group and HCC 48 Group. Hiraoka A, et al. Among authors: koshiyama y. Hepatol Res. 2024 Nov 11. doi: 10.1111/hepr.14136. Online ahead of print. Hepatol Res. 2024. PMID: 39526824
Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection who had received direct-acting antiviral therapy.
Tada T, Kurosaki M, Toyoda H, Tamaki N, Yasui Y, Nakamura S, Mori N, Tsuji K, Ochi H, Akahane T, Kobashi H, Fujii H, Marusawa H, Kondo M, Urawa N, Yoshida H, Uchida Y, Morita A, Hasebe C, Mitsuda A, Ogawa C, Narita R, Kubotsu Y, Matsushita T, Shigeno M, Okamoto E, Okada K, Kasai T, Ishii T, Nonogi M, Yasuda S, Koshiyama Y, Kumada T, Izumi N. Tada T, et al. Among authors: koshiyama y. Liver Int. 2024 Nov;44(11):3060-3071. doi: 10.1111/liv.16093. Epub 2024 Sep 2. Liver Int. 2024. PMID: 39223936
Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma.
Chuma M, Uojima H, Toyoda H, Hiraoka A, Arase Y, Atsukawa M, Itokawa N, Okubo T, Tada T, Numata K, Morimoto M, Sugimori M, Nozaki A, Iwasaki S, Yasuda S, Koshiyama Y, Mishima Y, Tsuruya K, Tokoro C, Miura Y, Hidaka H, Kumada T, Kusano C, Kagawa T, Maeda S. Chuma M, et al. Among authors: koshiyama y. Hepatol Int. 2024 Oct;18(5):1472-1485. doi: 10.1007/s12072-024-10680-8. Epub 2024 Jul 4. Hepatol Int. 2024. PMID: 38963640
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Among authors: koshiyama y. Aliment Pharmacol Ther. 2024 Jul;60(2):233-245. doi: 10.1111/apt.18037. Epub 2024 May 8. Aliment Pharmacol Ther. 2024. PMID: 38716823 Clinical Trial.
Prevalence of pruritus in patients with chronic liver disease: A multicenter study.
Oeda S, Takahashi H, Yoshida H, Ogawa Y, Imajo K, Yoneda M, Koshiyama Y, Ono M, Hyogo H, Kawaguchi T, Fujii H, Nishino K, Sumida Y, Tanaka S, Kawanaka M, Torimura T, Saibara T, Kawaguchi A, Nakajima A, Eguchi Y; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Oeda S, et al. Among authors: koshiyama y. Hepatol Res. 2018 Feb;48(3):E252-E262. doi: 10.1111/hepr.12978. Epub 2017 Oct 10. Hepatol Res. 2018. PMID: 28877392
Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS.
Ochi T, Kawaguchi T, Nakahara T, Ono M, Noguchi S, Koshiyama Y, Munekage K, Murakami E, Hiramatsu A, Ogasawara M, Hirose A, Mizuta H, Masuda K, Okamoto N, Suganuma N, Chayama K, Yamaguchi M, Torimura T, Saibara T. Ochi T, et al. Among authors: koshiyama y. Sci Rep. 2017 Aug 31;7(1):10146. doi: 10.1038/s41598-017-09256-4. Sci Rep. 2017. PMID: 28860506 Free PMC article.
28 results